e-learning
resources
Virtual 2020
Pre-Congress Content
Clinical monitoring and new therapies for cystic fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Blood gas analysis to predict survival in patients with cystic fibrosis
J. Kurz (Bern, Switzerland), B. Spycher (Bern, Switzerland), R. Rodriguez (Bern, Switzerland), R. Fischer Biner (Bern, Switzerland), P. Latzin (Bern, Switzerland), F. Singer (Bern, Switzerland)
Source:
Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Session:
Clinical monitoring and new therapies for cystic fibrosis
Session type:
E-poster session
Number:
358
Disease area:
-
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Kurz (Bern, Switzerland), B. Spycher (Bern, Switzerland), R. Rodriguez (Bern, Switzerland), R. Fischer Biner (Bern, Switzerland), P. Latzin (Bern, Switzerland), F. Singer (Bern, Switzerland). Blood gas analysis to predict survival in patients with cystic fibrosis. 358
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Lung clearance index is superior to moment ratios in the analysis of inert gas washouts in cystic fibrosis
Source: Eur Respir J 2007; 30: Suppl. 51, 338s
Year: 2007
Association of lung clearance index with survival in individuals with cystic fibrosis
Source: Eur Respir J, 59 (3) 2100432; 10.1183/13993003.00432-2021
Year: 2022
Sputum glucose as a marker of disease severity in adult patients with cystic fibrosis
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
The lung clearance index correlates with markers of pulmonary deterioration in patients with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013
Long-term course of lung clearance index among patients with cystic fibrosis
Source: Virtual Congress 2020 – Respiratory physiology and sleep: new approaches to diagnosis and treatment
Year: 2020
Factors predicting mortality in cystic fibrosis where lung transplantation can not be performed
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Year: 2012
Multiple dimensional analysis of arterial blood gas and pulmonary function in patients with COPD
Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD
Year: 2012
Determining why patients with idiopathic pulmonary fibrosis (IPF) have difficulty performing gas transfer
Source: Annual Congress 2013 –Airway calibre, airway challenge and assessment of oxygenation
Year: 2013
Proteomic analysis of sputum from adults with cystic fibrosis and COPD: identification of potential biomarkers for disease monitoring
Source: Eur Respir J 2006; 28: Suppl. 50, 152s
Year: 2006
Improved survival at low lung function in cystic fibrosis (CF)
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009
Pulmonary hypertension as a predictor of survival in cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 230s
Year: 2003
Lung function parameters influence serum concentration after antibiotic inhalation in patients with cystic fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 537s
Year: 2001
Changes in lung gas mixing after physiotherapy in adults with cystic fibrosis
Source: Annual Congress 2007 - Critical care and airways clearance
Year: 2007
Blood mitochondrial DNA as a biomarker of clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 56 (5) 2001769; 10.1183/13993003.01769-2020
Year: 2020
A contemporary survival analysis of individuals with cystic fibrosis: a cohort study
Source: Eur Respir J 2015; 45: 670-679
Year: 2015
Lung clearance index is reproducible and close to normal in stable cystic fibrosis patients post bilateral lung transplant
Source: Annual Congress 2009 - Human and experimental lung transplantation: novel findings
Year: 2009
Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
Assessment of regional resistance distribution using computational fluid dynamics in cystic fibrosis patients
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept